Seaport Therapeutics

BOSTON, August 31, 2026--Seaport Therapeutics to present at Citi's 2026 Biopharma Back to School Conference and participate in 21st Annual Wells Fargo Healthcare Conference

The latest company information, including net asset values, performance, holding & sectors weighting, changes in voting rights, and directors and dealings.

Prediction of Human Pharmacokinetic Profiles of Glyph Platform Prodrugs Using Animal and Human Data via a Semi-mechanistic Pharmacokinetic Model VIEW

Unlocking Medicines for Neuropsychiatry by Enhancing Oral Absorption Using a Lymphatic-targeting Prodrug Technology VIEW

GlyphAllo, a Novel, Orally Bioavailable Prodrug of Allopregnanolone, Induces an EEG Profile Consistent with GABAA Positive Allosteric Modulation in Healthy Volunteers VIEW

BOSTON, April 30, 2026 - Seaport Therapeutics, Inc., (Nasdaq: SPTX) ("Seaport" or the "Company"), a clinical-stage therapeutics company that is inventing and developing neuropsychiatric medicines, today announced the pricing of its upsized initial public

GlyphAgo achieved therapeutic exposures of agomelatine at doses projected to avoid liver enzyme elevations and reduce or eliminate the need for liver function testing that has previously limited agomelatine's clinical use GlyphAgo demonstrated a statistic

Predicted Liver Safety of GlyphAgo, a Lymphatic-targeting Prodrug of Agomelatine That Avoids First-pass Metabolism VIEW

Newly published findings further support clinical validation of Seaport's proprietary Glyph platform to enable oral dosing Data supported advancement of ongoing Phase 2b clinical trial of GlyphAllo in major depressive disorder (MDD) BOSTON, March 25, 2026